durect.com (DRRX): Company Cash on Hand

Corporate company logo of DURECT (DRRX)

DURECT Corporation (DRRX) develops unique epigenetic therapies for acute liver pathologies, leveraging its patent protection. Management focuses on innovative methods for regenerating damaged tissues. However, the clinical trial stage, coupled with a lack of sales, is increasing R&D expenses. The cash reserve trend demonstrates the available liquidity for operational needs, where the parameter value equals 0.01.

DURECT Corporation - DRRX Company Cash Balance (period 07/04/2022 - 09/27/2025)

Summary analytical data breakdowns for durect.com (DRRX)

- stock quotes and analyst forecast:
Fundamental valuation:DRRX DURECT Corp
Signature product of DURECT Corporation

The volume of liquid assets allows for the separation of DURECT Corporation (DRRX) internal financial stability from share price volatility, measuring the business's ability to fund operating activities without external borrowing. An analysis of the cash balance confirms the resource base for developing epigenetic treatments for liver failure, making therapy accessible without transplantation and guaranteeing the company's strategic autonomy.